Review On: Quality by Design (QbD) in Modern Pharmaceutical Development

Abstract

The pharmaceutical industry is currently undergoing a significant shift from empirical, reactive manufacturing strategies to a systematic, predictive framework known as Quality by Design (QbD). By transitioning from traditional post-production inspection—where quality is \"tested into\" the product—to a proactive strategy where quality is \"built into\" the design, organizations can better navigate the complexities of pharmaceutical development. This article provides an in-depth analysis of the QbD paradigm, anchored by the International Council for Harmonization (ICH) guidelines Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), and Q10 (Pharmaceutical Quality System). We delineate the critical transition from \"fixed\" manufacturing processes to flexible, science-based \"Design Spaces,\" supported by Process Analytical Technology (PAT) and real-time release testing. The review examines the integrated elements of QbD, including the formulation of the Quality Target Product Profile (QTPP), the systematic identification of Critical Quality Attributes (CQAs), and the application of Failure Mode and Effects Analysis (FMEA) for comprehensive risk mitigation. Furthermore, we explore how Design of Experiments (DoE) and multivariate data analysis (MVDA) serve as pillars for enhancing process understanding and enabling continuous lifecycle improvement. By evaluating the strategic implications of these methodologies, this review demonstrates how QbD not only ensures consistent patient safety and product efficacy but also provides significant economic advantages by reducing batch failure rates, accelerating regulatory approval timelines, and facilitating agile manufacturing in an increasingly globalized market.

Introduction

Quality by Design (QbD) is a modern pharmaceutical development approach that emphasizes building quality into a product from the earliest stages of design rather than relying solely on final product testing. Traditionally, pharmaceutical quality assurance depended on post-manufacturing inspection, which often failed to identify the root causes of product variability. Introduced by Dr. Joseph M. Juran, QbD is based on the principle that quality problems arise from poor product and process design rather than manufacturing execution. Today, regulatory agencies such as the FDA and the International Council for Harmonisation (ICH) promote QbD because it provides a scientific understanding of how Critical Process Parameters (CPPs) and raw material characteristics influence Critical Quality Attributes (CQAs), resulting in safer and more consistent pharmaceutical products.

The QbD framework is supported by three key ICH guidelines. ICH Q8 (R2) focuses on systematic pharmaceutical development, ICH Q9 provides a structured framework for Quality Risk Management (QRM), and ICH Q10 defines the Pharmaceutical Quality System (PQS) required to support product quality throughout its lifecycle. Adopting QbD offers several advantages, including improved process understanding through tools such as Design of Experiments (DoE) and Process Analytical Technology (PAT), reduced patient risk by proactively identifying factors affecting product quality, and continuous improvement through ongoing refinement of manufacturing processes and product knowledge.

Compared with the traditional pharmaceutical approach, QbD represents a significant shift in manufacturing philosophy. Traditional methods primarily rely on testing and inspection after production, use fixed manufacturing processes, and follow an empirical development strategy with limited lifecycle management. In contrast, QbD adopts a scientific and risk-based approach where quality is built into the product during development. It allows flexible manufacturing within a defined design space, supports continuous process verification and improvement, and reduces the need for extensive regulatory approvals when operating within validated process limits.

The effectiveness of QbD depends on several core elements. The Quality Target Product Profile (QTPP) defines the desired quality, safety, and efficacy characteristics of the final product before development begins. Critical Quality Attributes (CQAs) identify the physical, chemical, biological, or microbiological properties that must remain within specified limits to ensure product quality. Risk assessment, commonly performed using Failure Mode and Effects Analysis (FMEA), identifies and prioritizes factors that could compromise product quality. The Design Space specifies the acceptable range of process parameters and material attributes that consistently produce high-quality products, while the Control Strategy establishes monitoring and control measures to maintain product quality throughout the manufacturing lifecycle.

Several advanced methodologies support successful QbD implementation. Design of Experiments (DoE) is a statistical tool used to evaluate multiple process variables simultaneously, unlike the traditional One Variable at a Time (OVAT) approach. DoE identifies optimal process conditions, determines statistically significant factors affecting product quality, and enables efficient process optimization. Process Analytical Technology (PAT) complements DoE by enabling real-time monitoring of manufacturing processes using analytical techniques such as Near-Infrared (NIR) spectroscopy, Raman spectroscopy, and High-Performance Liquid Chromatography (HPLC). PAT allows manufacturers to monitor CPPs continuously and make immediate process adjustments to maintain operation within the design space, thereby reducing product variability and preventing failures.

Risk management is another essential component of QbD. Failure Mode and Effects Analysis (FMEA) systematically evaluates potential process failures by assessing their severity, likelihood of occurrence, and detectability. Based on these factors, risks are prioritized so that resources can be focused on controlling the most critical aspects of the manufacturing process. Additionally, mathematical modeling and simulation techniques enhance QbD by predicting manufacturing outcomes without performing costly physical experiments. Mechanistic models describe process behavior mathematically, Computational Fluid Dynamics (CFD) simulates material movement within manufacturing equipment to optimize mixing and blending, and predictive models facilitate smooth scale-up from laboratory production to commercial manufacturing.

QbD has wide-ranging applications throughout pharmaceutical development. During drug substance and excipient selection, researchers evaluate material properties such as particle size, crystallinity, and moisture content to ensure product stability and bioavailability while performing compatibility studies to prevent adverse interactions between ingredients. In analytical method development, DoE is used to establish robust analytical methods and validate techniques such as HPLC and UV spectroscopy, ensuring reliable impurity detection and quality monitoring. In formulation and process development, QTPP is established first, followed by design space mapping through systematic experimentation to optimize manufacturing parameters and ensure consistent product quality during scale-up.

QbD also improves stability testing and shelf-life prediction by using scientific understanding of degradation pathways to model the effects of temperature, humidity, and environmental conditions on product stability. This enables better prediction of shelf life and more effective packaging and storage strategies. In regulatory filings and lifecycle management, QbD provides manufacturers with greater regulatory flexibility because scientifically established design spaces allow process modifications without requiring extensive regulatory approval. Supported by the Pharmaceutical Quality System outlined in ICH Q10, QbD encourages continuous monitoring and ongoing process improvement throughout the entire product lifecycle.

Conclusion

This is a simple terms, adopting Quality by Design (QbD) changes pharmaceutical manufacturing from a reactive process of trial-and-error into a proactive, science-driven strategy. By thoroughly understanding the science behind how a medicine is made—from the quality of the raw materials to the settings on the machines—manufacturers can \"build\" quality into the product from the very start rather than simply hoping for the best and testing it at the end. This shift ensures that every batch produced is consistent and reliable, which significantly reduces the chances of failure and helps prevent medicine shortages for patients. Furthermore, because the process is based on proven scientific data, companies gain the flexibility to make minor adjustments without needing lengthy regulatory approvals, ultimately leading to a more efficient and agile manufacturing environment. In conclusion, QbD represents a smarter, more modern approach to medicine production that prioritizes patient safety through deep scientific insight and continuous improvement throughout the entire lifecycle of a drug.

References

[1] Darkunde, S. L. (2018). A review on quality by design. Int J Pharm Chem Anal, 5(1), 1-6. [2] Kumar, V. P., & Gupta, N. V. (2015). A review on quality by design approach (QBD) for pharmaceuticals. Int. J. Drug Dev. Res, 7(1), 52-60. [3] Kengar, M. D., Tamboli, J. A., & Magdum, C. (2019). Quality by design-a review. PharmaTutor, 7(4), 48-51. [4] Yu, L. X., Amidon, G., Khan, M. A., Hoag, S. W., Polli, J., Raju, G. K., & Woodcock, J. (2014). Understanding pharmaceutical quality by design. The AAPS journal, 16(4), 771-783. [5] Kumar, V. P., & Gupta, N. V. (2015). A review on quality by design approach (QBD) for pharmaceuticals. Int. J. Drug Dev. Res, 7(1), 52-60. [6] Chauhan, P., Modi, D., Seema Banu, M., Giri, S., Rathod, A., Patel, K. K., & Patel, D. C. (2022). Review on analytical quality by design and pat. World Journal of Pharmaceutical Research, 11(14), 244-266. [7] Patil, A. S., & Pethe, A. M. (2013). Quality by Design (QbD): A new concept for development of quality pharmaceuticals. Int J Pharm Qual Assur, 4(2), 13-9. [8] Nadpara, N. P., Thamar, R. V., Kalola, V. N., & Patel, P. B. (2012). Quality by design (QBD): A complete review. Int J Pharm Sci Rev Res, 17(2), 20-8. [9] Abhinandana, P., & Nadendla, R. Application of Quality by Design and its Parameters for Pharmaceutical Products. [10] Gawade, A., Chemate, S., & Kuchekar, A. (2013). Pharmaceutical Quality by Design: A new approach in product development. Research and Reviews: Journal of Pharmacy and Pharmaceutical Sciences, 2(3), 5-12. [11] Khan, A., Naquvi, K. J., Haider, M. F., & Khan, M. A. (2024). Quality by design-newer technique for pharmaceutical product development. Intelligent Pharmacy, 2(1), 122-129. [12] Patil, H. D., Patil, C. B., Patil, V. V., & Patil, P. S. (2023). An overview on quality by design. [13] Patel, H., Parmar, S., & Patel, B. (2013). A comprehensive review on quality by design (QbD) in pharmaceuticals. development, 4(5). [14] Rajora, A., & Chhabra, G. U. R. M. E. E. T. (2021). Quality by design approach: Regulatory need, current, and future perspective. Asian J. Pharm. Clin. Res, 14, 29-35. [15] Raghav, G., VIPIN, S., SURESH, J., & Ankit, G. (2014). A review on Quality by Design approach: regulatory need. Mintage Journal of Pharmaceutical & Medical Science. Review article, 3(Suppl 3), 20-26. [16] Mogal, V., Dusane, J., Borase, P., Thakare, P., & Kshirsagar, S. (2016). A review on quality by design. Pharm Biol Eval, 3, 313-9. [17] Ganzer, W. P., Materna, J. A., Mitchell, M. B., & Wall, L. K. (2005). Current thoughts on critical process parameters and API synthesis. Pharmaceutical technology (2003), 29(7), 46-66. [18] Mogal, V., Dusane, J., Borase, P., Thakare, P., & Kshirsagar, S. (2016). A review on quality by design. Pharm Biol Eval, 3, 313-9. [19] Shree, V. M., & Chandramouli, R. (2021). Review on Quality by Design Approach (Qbd). Current Trends in Biotechnology and Pharmacy, 15(4), 447-454. [20] Sangs Hetti, J. N., Deshpande, M., Zaheer, Z., Shinde, D. B., & Arote, R. (2017). Quality by design approach: Regulatory need. Arabian Journal of chemistry, 10, S3412-S3425.

Copyright

Copyright © 2026 Miss. Sayali Rajesh Bhalsen, Mr. Nilesh D. Zanzane, Dr. Nitin M Gawai, Miss. Asmita D Tengle, Miss. Vaidehi V Tukrul. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.